BioArctic AB (BRCTF) Stock Price & Analysis
BioArctic AB (BRCTF) — price $30.33 (0.00%), as of the Nov 18, 2026 trading session; market cap $2.69B.
Educational signal · not a buy or sell recommendation · How to read this
BioArctic AB · BRCTF
BioArctic AB (publ) is a Swedish biopharmaceutical company focused on developing innovative treatments for central nervous system disorders. Their lead candidate, Lecanemab, targets Alzheimer's disease and is in late-stage clinical development through a collaboration with Eisai.
Price as of Nov 18, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $30.33 | |
| Change on the day | 0.00% | |
| 52-week range | $29.40 – $40.00 | |
| Market capitalisation | $2.69B | |
| Price / earnings (trailing) | 256.13 | |
| Shares traded on the day | 3.3K |
Price & events
Other perspectives
Council score for BioArctic AB (BRCTF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 5, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is BioArctic AB (BRCTF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. BioArctic AB (BRCTF) is the company analyzed here. It employs 131 people and is led by Gunilla Christina Osswald. In Q2 FY2026 it reported revenue of kr248M and net income of -kr11M. The market values it at $2.69B.
What do the latest results show for BioArctic AB (BRCTF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of kr248M. Against analyst estimates the company has EPS beat 7 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | kr248M | -kr11M | -kr0.12 (diluted) |
| Q1 FY2026 | kr438M | kr212M | kr2.39 (diluted) |
| Q4 FY2025 | kr184M | -kr9M | -kr0.10 (diluted) |
| Q3 FY2025 | kr133M | -kr87M | -kr0.98 (diluted) |
What are the financial strengths and risks for BioArctic AB (BRCTF)?
Short answer · as of
The distress and quality screens read Altman Z 21.95 · Piotroski F 4. Trailing ratios: ROE 5.2% · ROA 3.7% · current ratio 3.99 · earnings yield 0.4% · free-cash-flow yield 0.4%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BRCTF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BRCTF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
BioArctic AB Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the BRCTF research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is BRCTF a good stock to buy?
Stock Expert AI does not rate BRCTF buy, sell or hold. BioArctic AB has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BRCTF stock price today?
The last price recorded for BioArctic AB (BRCTF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for BRCTF?
The primary risks for BioArctic AB (publ) revolve around the clinical development and regulatory approval of its drug candidates, particularly Lecanemab for Alzheimer's disease.
What are the key factors to evaluate for BRCTF?
Evaluate BRCTF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Investing in R&D to expand the pipeline with innovative programs could yield future blockbuster drugs. Not financial advice.
How frequently does BRCTF data refresh on this page?
BRCTF's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BRCTF's recent stock price performance?
BioArctic AB (BRCTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative antibody technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BRCTF overvalued or undervalued right now?
The trailing P/E of BioArctic AB (BRCTF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BRCTF before investing?
Before investing in BioArctic AB (BRCTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 9 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com